New Drug Product: Ajovy

This slideshow reviews drug information for Ajovy. Click here for the complete Ajovy new product monograph. For a downloadable PDF of this slideshow, click here.

First-of-its-Kind Migraine Drug Gets FDA Approval

The efficacy of Aimovig was evaluated as a preventive treatment of episodic or chronic migraine in 3 randomized, double-blind, placebo-controlled studies: 2 studies in patients with episodic migraine (4-14 migraine days per month) and 1 study in patients with chronic migraine (≥15 headache days per month with ≥8 migraine days per month).